US4771046A - Carbapenem derivatives - Google Patents

Carbapenem derivatives Download PDF

Info

Publication number
US4771046A
US4771046A US06/856,696 US85669686A US4771046A US 4771046 A US4771046 A US 4771046A US 85669686 A US85669686 A US 85669686A US 4771046 A US4771046 A US 4771046A
Authority
US
United States
Prior art keywords
group
methyl
hydroxyethyl
multiplet
carbapen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/856,696
Other languages
English (en)
Inventor
Isao Kawamoto
Rokuro Endo
Masayuki Iwata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Assigned to SANKYO COMPANY, LIMITED reassignment SANKYO COMPANY, LIMITED ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: ENDO, ROKURO, IWATA, MASAYUKI, KAWAMOTO, ISAO
Application granted granted Critical
Publication of US4771046A publication Critical patent/US4771046A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a series of new carbapenem compounds and to compositions containing the compounds, and provides processes for preparing these compounds.
  • penicillins form a well known class of antibiotics, which have found considerable use in human and animal therapy for many years. Chemically, the penicillins have in common a ⁇ -lactam structure, commonly referred to as "penam”, which may be represented by the following formula: ##STR4##
  • carbapenem structure that is compounds having a carbon atom in place of the sulfur atom at the 1-position and having a double bond between the carbon atoms in the 2- and 3-positions of the basic penam structure.
  • the carbapenem structure may be represented by the following formula: ##STR5##
  • carbapenem derivatives Of the known carbapenem derivatives, the best known is a compound called "thienamycin", whose semi-systematic name is 2-(2-aminoethylthio)-6-(1-hydroxyethyl)carbapen-2-em-3-carboxylic acid.
  • thienamycin Although thienamycin is known to have remarkably potent and broad antibacterial activity, its chemical stability in the human body is poor, which restricts its practical use.
  • Various attempts have, therefore, been made to modify the chemical structure of thienamycin in order to improve its chemical stability whilst maintaining or improving its superior activity, but there is still a continuing need to develop further carbapenem antibiotics with improved properties.
  • an object of the present invention to provide a new group of carbapenem derivatives which possess superior absorption and metabolic stability (as evidenced by improved recovery rates in the urine), as well as a broad antibacterial spectrum and low toxicity. Further objects of the invention are to provide synthetic processes for the preparation of the said new carbapenem derivatives, and to provide pharmaceutical compositions comprising the said derivatives suitable for human and animal administration.
  • X represents a hydrogen atom or a methyl group
  • Y represents a group of the formula: ##STR7## in which:
  • Z represents an oxygen atom or two hydrogen atoms
  • R 1 represents a hydrogen atom, a C 1-4 alkyl group, a C 1-4 alkanoyl grpoup, or a C 1-4 alkanesulfonyl group;
  • R 2 represents a hydrogen atom or a hydroxy group, and R 3 represents a carbamoyl group;
  • R 2 represents a carbamoyloxy group, and R 3 represents a hydrogen atom or a carbamoyl group;
  • R 4 represents a hydrogen atom or a C 1-4 alkyl group; and ##STR8## represents a 4-6 membered saturated heterocyclic group in which the indicated nitrogen atom is the only hetero-atom;
  • R 1 when R 1 represents a C 1-4 alkyl group this may be straight or branched, for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or t-butyl.
  • R 1 represents a C 1-4 alkanoyl group this may be straight or branched, for example formyl, acetyl, propionyl, butyryl or isobutyryl.
  • R 1 represents a C 1-4 alkanesulfonyl group
  • the alkane portion of this may be, for example, any of the above-mentioned C 1-4 alkyl groups.
  • R 4 represents a C 1-4 alkyl group it may be, for example, any of those mentioned above for R 1 .
  • the 4-6 membered nitrogen-containing saturated heterocyclic group may be, for example, azetidinyl, pyrrolidinyl or piperidyl.
  • a preferred sub-group of the compounds of the invention are those wherein R 1 represents a hydrogen atom, a methyl group, an acetyl group or a mesyl (i.e. methanesulfonyl) group. Also preferred are those compounds in which Y represents a 3-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, carbamoyloxypyrrolidin-1-yl, hydroxyiminopiperidin-1-yl or methoxyiminopiperidin-1-yl group. Particularly preferred compounds are those wherein R 1 represents a hydrogen atom or a methyl group, and Y represents a 3-oxopiperazin-1-yl or 4-methyl-3-oxopiperazin-1-yl group.
  • the compounds of the invention are also capable of forming external salts and esters.
  • the nature of such salts and esters is not critical to the present invention and the compounds of formula (I) are capable of forming salts and esters with any cations and ester-forming alcohols, respectively, which are known for the formation of salts and esters with compounds of this type.
  • the only restriction on the nature of such salts and esters is that they should be "pharmaceutically acceptable" which means to those skilled in the art that the salt-forming cation or ester-forming alcohol should not, or should not to an unacceptable extent, reduce the activity of the compounds of formula (I), nor should they increase, or increase to an unacceptable extent, the toxicity of those compounds.
  • the formation of salts and esters and the application of these criteria to the choice of salt-forming cations or ester-forming alcohols is so well-known to the man skilled in the art as to require no further definition here.
  • esters examples include: C 1 -C 6 preferably C 1 -C 4 , alkyl esters, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl and t-butyl esters; C 1 -C 6 , preferably C 1 -C 4 , haloalkyl esters, which may have one or more halogen atoms (the maximum number of halogen atoms being dictated by the number of carbon atoms in the alkyl group, but preferably being from 1 to 3), such as the 2-iodoethyl, 2,2-dibromoethyl and 2,2,2-trichloroethyl esters; alkoxymethyl esters, wherein the alkoxy part has from 1 to 6, preferably from 1 to 4, carbon atoms, for example the methoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl and isobutoxymethyl esters; aliphatic carboxylic acy
  • the compounds of formula (I) are also capable of forming external acid-addition salts.
  • the nature of the acids employed to form these salts is not critical and is only limited, where the compounds of the invention are intended for pharmaceutical use, by the requirement that the resulting acid-addition salts should be pharmaceutically acceptable. Accordingly, a wide range of acids can be employed to form such acid-addition salts. Examples include: such mineral acids as hydrochloric acid and hydrobromic acid; and such organic acids as oxalic acid, tartaric acid, citric acid, maleic acid and succinic acid. Hydrochloric acid is preferred.
  • the compounds of formula (I) can also form salts with a wide variety of cations.
  • salts which may be employed in the present invention include: metal salts, particularly alkali metal or alkaline earth metal salts, such as the lithium, sodium, potassium, calcium or magnesium salts; salts with basic amino acids, such as lysine or arginine; ammonium salts; and salts with organic amines, such as cyclohexylamine, diisopropylamine or triethylamine.
  • metal salts particularly alkali metal or alkaline earth metal salts, such as the lithium, sodium, potassium, calcium or magnesium salts
  • salts with basic amino acids such as lysine or arginine
  • ammonium salts such as cyclohexylamine, diisopropylamine or triethylamine.
  • the alkali metal, particularly sodium and potassium, salts are preferred.
  • the compounds of the present invention can exist in the form of various optical isomers and stereoisomers, due to the presence of asymmetric carbon atoms. Although all of these isomers are represented herein by a single formula, it should be understood that the present invention embraces the individual isolated isomers as well as mixtures of isomers.
  • the preferred isomers are those having the (5R,6S) configuration or (in the case of compounds substituted with methyl at the 1-position) having the (1R,5S,6S) configuration.
  • the hydroxy group at the ⁇ -position of the 6-substituent is preferably in the R-configuration.
  • Examples of preferred compounds of formula (I) are given in the following Table 1, defined in terms of the substituents X and Y.
  • Table 1 The preparation of compounds 1-4, 9, 10, 15-22 and 25-29 is illustrated hereinafter in the Examples, where these compounds are referred to by the numbers used in Table 1 and where the configuration of the individual isomers is specified.
  • the configuration of substituents is not specified and each of the compounds may be in any of the possible configurations, or may be a mixture of isomers.
  • the listed compounds preferably have the (5R,6S) or (1R,5S,6S) configuration, and the hydroxy group at the ⁇ -position of the 6-substituent is preferably in the R-configuration, as already described.
  • the carboxy-protecting group R 9 may be for example an alkyl group (such as methyl, ethyl or t-butyl), an aralkyl group (such as benzyl, diphenylmethyl, 2-nitrobenzyl or 4-nitrobenzyl), an alkenyl group (such allyl, 2-chloroallyl or 2-methylallyl), a haloalkyl group (such 2,2,2-trichloroethyl, 2,2-dibromoethyl or 2,2,2-tribromoethyl), or a 2-trimethylsilylethyl group.
  • an alkyl group such as methyl, ethyl or t-butyl
  • an aralkyl group such as benzyl, diphenylmethyl, 2-nitrobenzyl or 4-nitrobenzyl
  • an alkenyl group such allyl, 2-chloroallyl or 2-methylallyl
  • a haloalkyl group such 2,2,2-trichlor
  • R 10 represents a leaving group, which may be an alkanesulfonyl group (such as methanesulfonyl, ethanesulfonyl, propanesulfonyl, isopropanesulfonyl or butanesulfonyl), an arylsulfonyl group (such as phenylsulfonyl, tolylsulfonyl or naphthylsulfonyl), a dialkylphosphoryl group (such as dimethylphosphoryl, diethylphosphoryl, dipropylphosphoryl, diisopropylphosphoryl, dibutylphosphoryl or dipentylphosphoryl), or a diarylphosphoryl group (such as diphenylphosphoryl or ditolylphosphoryl).
  • alkanesulfonyl group such as methanesulfonyl, ethanesulfonyl, propanesulfonyl, isopropanesulfonyl or but
  • the starting materials of formula (II) used in Process A are all compounds which are known per se.
  • the compound of formula (III) is prepared by reacting the starting material of formula (II) with a reagent capable of giving the leaving group R 10 .
  • the reagent used for this may be an anhydrous alkanesulfonic acid (e.g. methanesulfonic or ethanesulfonic acid), an anhydrous arylsulfonic acid (e.g. benzenesulfonic or p-toluenesulfonic acid), a dialkylphosphoryl halide (e.g. dimethylphosphoryl chloride or diethylphosphoryl chloride), or a diarylphosphoryl halide (e.g. diphenylphosphoryl chloride or diphenylphosphoryl bromide).
  • the preferred reagent is anhydrous p-toluenesulfonic acid or diphenylphosphoryl chloride.
  • the reaction is preferably effected in the presence of a base, the nature of which is not critical, provided that it has no adverse effect on the reaction or upon the reagents, in particular on the ⁇ -lactam ring.
  • a base such as triethylamine or diisopropylethylamine, or an inorganic base such as potassium carbonate or sodium carbonate.
  • an inert solvent the nature of which is likewise not critical, provided that it has no adverse effect upon the reaction.
  • the solvent may suitably be a halogenated hydrocarbon (such as methylene chloride, 1,2-dichloroethane or chloroform), a nitrile (such as acetonitrile), or an amide (such as N,N-dimethylformamide or N,N-dimethylacetamide).
  • a halogenated hydrocarbon such as methylene chloride, 1,2-dichloroethane or chloroform
  • a nitrile such as acetonitrile
  • an amide such as N,N-dimethylformamide or N,N-dimethylacetamide.
  • the resulting compound of formula (III) can be used in the next step of Process A without isolating it from the reaction mixture.
  • the compound of formula (V) is prepared by reacting the compound of formula (III) with a mercaptan of formula ##STR10## wherein Y is as defined above.
  • This reaction is preferably carried out in the presence of a base and of an inert solvent, such as those already mentioned in connection with the previous reaction step.
  • the reaction temperature used will normally be in the range of from about -20° C. to room temperature, although this is not particularly critical; and the time required for the reaction will generally be from about 30 minutes to 8 hours.
  • the resulting product of formula (V) may, if desired, be recovered from the reaction mixture by conventional means.
  • one suitable procedure comprises evaporating off the solvent from the reaction solution or mixture, adding a water-immiscible organic solvent to the residue, washing the resulting mixture with water and, if necessary, drying it, and finally evaporating off the solvent to give the desired product.
  • the resulting product may be further purified by a variety of conventional techniques adapted to the precise nature of the product, such as recrystallization, reprecipitation, or the various chromatographic techniques, for example column chromatography or preparative thin layer chromatography.
  • the product of formula (V) can be subjected to the final reaction step of Process A without isolating it from the reaction mixture.
  • the final reaction step of process A comprises the removal of the carboxy-protecting group R 9 from the compound of formula (V), to give the corresponding carboxylic acid of formula (I).
  • This step is optional, and it will be appreciated that the removal of the carboxy-protecting group may not always be necessary or desired, for example when the compound of formula (V) is a pharmaceutically acceptable ester within the scope of the present invention. If it is desired to remove the carboxy-protecting group, this may be done by the use of conventional methods, the choice of which will depend upon the nature of the protecting group employed.
  • the protecting group is removable by reduction, for example if it is a haloalkyl group, an aralkyl group or a benzhydryl group, it may be removed by contact with a reducing agent.
  • a reducing agent is a combination of zinc with acetic acid.
  • the protecting group is an aralkyl group (such as a benzyl or p-nitrobenzyl group) or a benzhydryl group
  • a suitable catalyst such as platinum or palladium on carbon
  • an alkali metal sulfide such as sodium sulfide or potassium sulfide.
  • the reduction process is preferably effected in the presence of a solvent, the nature of which is not critical, provided that it has no adverse effect upon the reaction.
  • Suitable solvents include alcohols (such as methanol or ethanol), ethers (such as tetrahydrofuran or dioxane), aliphatic carboxylic acids (such as acetic acid), or a mixture of one or more of these organic solvents with water.
  • the reaction temperature is not critical but will normally be in the range from 0° C. to room temperature.
  • the time required for the reaction will vary, depending upon the nature of the starting materials and reducing agents, as well as upon the reaction temperature, but a period of from 5 minutes to 12 hours will normally suffice.
  • the desired compound which will contain a free carboxy group, may be recovered by conventional means from the reaction mixture.
  • a suitable recovery technique comprises: separating off any insolubles; and then distilling off the solvent to give the desired product. This may, if necessary, be further purified by conventional means, for example recrystallization or the various chromatography techniques, such as preparative thin layer chromatography or column chromatography.
  • R 9 represents a C 1-6 alkyl group (e.g. methyl, ethyl, propyl or isopropyl), a C 1-6 haloalkyl group (e.g.
  • fluoromethyl chloromethyl, fluoroethyl, chloroethyl, fluoropropyl, difluoromethyl, difluoroethyl, dichloroethyl, trifluoromethyl or trifluoroethyl
  • 2-acetylaminoethyl group a 2-acetylaminovinyl group
  • C 6-10 aryl group e.g. phenyl or naphthyl
  • pyridine or pyrimidine which may be optionally substituted with up to three substituents.
  • the optional substituents on the aryl group may be the same or different and are selected from halogen atoms (e.g. fluorine, chlorine or bromine), and C 1-6 alkyl (e.g. methyl, ethyl, propyl or isopropyl), C 1-6 alkoxy (e.g. methoxy, ethoxy, propoxy or isopropoxy), C 1-6 alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl), nitro, hydroxy and cyano groups.
  • halogen atoms e.g. fluorine, chlorine or bromine
  • C 1-6 alkyl e.g. methyl, ethyl, propyl or isopropyl
  • C 1-6 alkoxy e.g. methoxy, ethoxy, propoxy or isoprop
  • the optional substituents on the heteroaryl group may be the same or different and are selected from halogen atoms (e.g. fluorine, chlorine or bromine) and C 1-6 alkyl groups (e.g. methyl, ethyl, propyl or isopropyl).
  • halogen atoms e.g. fluorine, chlorine or bromine
  • C 1-6 alkyl groups e.g. methyl, ethyl, propyl or isopropyl.
  • the starting materials of formula (VI), used in Process B can be synthesized by the methods disclosed in the published European Patent Specifications No. EP-A-71908 and No. EP-A-102239.
  • the compound of formula (VI) is oxidized to the compound of formula (VII).
  • This oxidation can be effected by reacting the compound of formula (VI) with about 1.0 to 1.5 equivalents of hydrogen peroxide, or a peracid such as peracetic acid, trifluoroperacetic acid, perbenzoic acid or 3-chloroperbenzoic acid.
  • the reaction can suitably be carried out at a temperature of from about -40° to 50° C., with a reaction time of from about 0.5 to 24 hours, in a solvent such as methylene chloride, chloroform, 1,2-dichloroethane, methanol, ethanol, acetic acid, water, or a mixture of such solvents.
  • a solvent such as methylene chloride, chloroform, 1,2-dichloroethane, methanol, ethanol, acetic acid, water, or a mixture of such solvents.
  • the resulting product of formula (VII) can be isolated and purified by conventional techniques.
  • the compound of formula (VIII) is prepared by reacting the compound of formula (VII) with a mercaptan of formula ##STR12## wherein Y is as defined above.
  • This reaction is preferably carried out in the presence of a base and of an inert solvent.
  • the choice of the base and solvent, and of the other reaction conditions, may suitably be the same as for the corresponding step in Process A described above, for the production of the compound of formula (V) from the compound of formula (III).
  • the resulting product of formula (V) may optionally be isolated from the reaction mixture and purified, in the same manner as already described above with respect to Process A.
  • the compound of formula (V) may also optionally be converted to the corresponding free carboxylic acid of formula (I), by removal of the carboxy-protecting group R 9 , and the resulting product may be isolated and purified, again as described for the corresponding step in Process A.
  • the final product obtained by either Process A or Process B described above may, if desired, be salified and/or esterified by conventional means, to give salts and/or esters thereof, examples of such salts and esters being given previously.
  • the compounds provided by the invention exhibit outstanding antibacterial activity with a wide spectrum, as well as ⁇ -lactamase inhibiting activity. As assessed by the agar plate dilution method, they have been shown to be active against a wide range of pathogenic microorganisms, including both Gram-positive bacteria (such as Staphylococcus aureus and Bacillus subtilis) and Gram-negative bacteria (such as Escherichia coli, Shigella flexneri, Klebsiella pneumoniae, Proteus vulgaris, Serratia species e.g. Serratia marcescens, Enterobacter species e.g.
  • Enterobacter cloacae Salmonella enteritidis and Pseudomonas aeruginosa
  • Enterobacter cloacae Salmonella enteritidis and Pseudomonas aeruginosa
  • thienamycin and its analogs are inactivated in vivo in mammals by dehydropeptidase I
  • the compounds of the invention are much more stable to this enzyme and exhibit good urinary recovery, and thus possess good biological activity. They also exhibit low toxicity when tested in laboratory animals: for example, mice survive at dosages of above 2,000 mg/kg of compounds 3, 15 and 27 from the list in Table 1 above.
  • Table 2 sets out the activities of six of the compounds of the present invention against various bacteria, in terms of their minimal inhibitory concentrations ( ⁇ g/ml). These compounds are identified by the same numbers as used in Table 1 above.
  • compounds 1, 15 and 27 have the (5R,6S) configuration
  • compounds 2, 16 and 28 have the (1R,5S,6S) configuration.
  • the configuration of the hydroxy group in the side-chain at position 6 is (1R).
  • the compounds of the invention may be administered either orally or parenterally for the treatment of diseases in humans and other animals caused by pathogenic microorganisms.
  • the compounds may be formulated into any conventional forms for administration.
  • suitable formulations include tablets, granules, capsules, powders and syrups
  • parenteral administration include injectable solutions for intramuscular or, more preferably intravenous, injection.
  • the compounds of the invention are preferably administered parenterally, particularly in the form of an intravenous injection.
  • the dose of the compound of the invention will vary, depending upon the age, body weight and condition of the patient, as well as upon the form and times of administration. However, in general the adult daily dose is from 100 to 3000 mg of the compound, which may be administered in a single dose or in divided doses.
  • the concentrate was crystallized by adding ether, and the crystals were collected by filtration and washed with ether, giving 1.25 g of 2-[(3R)-3-carbamoyloxypyrrolidin-1-yl]-2-iminoethylmercaptan hydrochloride.
  • This material was dissolved in a mixture of 35 ml of tetrahydrofuran and 35 ml of 0.1M phosphate buffer (pH 7.0), and the solution was subjected to catalytic hydrogenation for 3 hours at room temperature in the presence of 0.55 g of 10% palladium-carbon.
  • the hydrogenated solution was filtered over "Celite” (Trade Mark) filter aid, and the filtrate was extracted with 80 ml of ether.
  • the aqueous layer was concentrated under reduced pressure, and the concentrate was subjected to chromatography through a 160 ml of column of "Dowex 50W" (Trade Mark) cation exchange resin (Na + type), giving 70 mg of the title product from the fraction eluted with water.
  • This material was dissolved in a mixture of 20 ml of tetrahydrofuran, 7 ml of water and 23 ml of 0.1M phosphate buffer (pH 7.0), and the solution was subjected to catalytic hydrogenation at room temperature for 4 hours in the presence of 0.3 g of 10% palladium-carbon.
  • the hydrogenated solution was filtered over "Celite” (Trade Mark) filter aid, the filtrate was extracted with 200 ml of ether, and the aqueous layer was concentrated under reduced pressure.
  • the concentrate was subjected to chromatography using a 300 ml column of "Dowex 50W" (Trade Mark) cation exchange resin (Na + type), and 27 mg of the title compound were obtained from the fraction eluted with water.
  • the concentrate was mixed with isopropanol, and the crystals which separated out were collected by filtration and reprecipitated from a mixture of ethanol and ether, giving 850 mg of 2-(4-methoxyiminopiperidin-1-yl)-2-iminoethylmercaptan hydrochloride.
  • This material was dissolved in a mixture of 20 ml of tetrahydrofuran, 7 ml of water and 23 ml of 0.1M phosphate buffer (pH 7.0), and the solution was subjected to catalytic hydrogenation at room temperature for 3 hours in the presence of 0.3 g of 10% palladium-carbon.
  • the product was worked up and purified in the same manner as in Example 2, giving 18 mg of the title compound.
  • This material was dissolved in a mixture of 20 ml of tetrahydrofuran, 7 ml of water and 23 ml of 0.1M phosphate buffer (pH 7.0), and the solution was subjected to catalytic hydrogenation at room temperature for 2 hours in the presence of 0.3 g of 10% palladium-carbon.
  • the product was worked up and purified in the same manner as in Example 2, giving 23 mg of the title compound.
  • This material was dissolved in a mixture of 20 ml of tetrahydrofuran, 7 ml of water and 23 ml of 0.1M phosphate buffer (pH 7.0), and the solution was catalytically hydrogenated at room temperature for 2 hours in the presence of 0.3 g of 10 % palladium-carbon.
  • the product was worked up and purified in the same manner as in Example 2, giving 15 mg of the title compound.
  • reaction mixture was then added to a mixture of 2.1 ml of diisopropylethylamine in 70 ml of tetrahydrofuran and 60 ml of 0.1M phosphate buffer solution (pH 7.0), which had been cooled with ice and salt, together with 10 ml of an aqueous solution of 3.17 g of 2-(4-carbamoyloxypiperidin-1-yl)-2-iminoethylmercaptan hydrochloride, and the resulting mixture was stirred for 5 minutes.
  • the reaction mixture was then subjected to hydrogenation at room temperature for 2 hours, in the presence of 3.0 g of 10% palladium-carbon.
  • the hydrogenated reaction mixture was worked up in the same manner as in Example 1(3), giving 783 mg of the title compound.
  • the concentrate was crystallized by adding ether, and the crystals were collected by filtration and washed with ether, giving 6.4 g of 2-(3-oxopiperazin-1-yl)-2-iminoethylmercaptan hydrochloride.
  • reaction mixture was then added to an ice-cooled mixture of 1.86 ml of diisopropylethylamine in 180 ml of tetrahydrofuran and 160 ml of 0.1M phosphate buffer solution (pH 7.0), together with 20 ml of an aqueous solution of 2.79 g of 2-(3-oxopiperazin-1-yl)-2-iminoethylmercaptan hydrochloride, and the resulting mixture was stirred for 50 minutes. The reaction mixture was then subjected to hydrogenation at room temperature for 2.5 hours, in the presence of 3.0 g of 10% palladium-carbon.
  • the hydrogenated mixture was filtered over "Celite” (Trade Mark) filter aid, and the filtrate was extracted with 200 ml of ether.
  • the aqueous layer was concentrated under reduced pressure, and the concentrate was subjected to chromatography through a 250 ml column of "Dowex 50W” (Trade Mark) cation exchange resin (Na + type), giving 850 mg of the title product from the fraction eluted with water.
  • This material was dissolved in a mixture of 40 ml of tetrahydrofuran and 46 ml of 0.1M phosphate buffer (pH 7.0), and the solution was subjected to hydrogenation for 2 hours at room temperature in the presence of 662 mg of 10% palladium-carbon.
  • the hydrogenated mixture was filtered over "Celite” (Trade Mark) filter aid, and the filtrate was extracted with 80 ml of ether.
  • the aqueous layer was concentrated under reduced pressure, and the concentrate was subjected to chromatography through a 160 ml column of "Dowex 50W" (Trade Mark) cation exchange resin (Na + type), giving 58 mg of the title product from the fraction eluted with water.
  • This material was dissolved in a mixture of 40 ml of tetrahydrofuran and 46 ml of 0.1M phosphate buffer (pH 7.0), and the solution was subjected to hydrogenation for 2 hours at room temperature in the presence of 0.6 g of 10% palladium-carbon.
  • the hydrogenation mixture was filtered over "Celite” (Trade Mark) filter aid, and the filtrate was extracted with 80 ml of ether.
  • the aqueous layer was concentrated under reduced pressure and the concentrate was subjected to chromatography through a 160 ml column of "Dowex 50W" (Trade Mark) cation exchange resin (Na + type), giving 132 mg of the title product from the fraction eluted with water.
  • This material was dissolved in a mixture of 40 ml of tetrahydrofuran and 46 ml of 0.1M phosphate buffer (pH 7.0), and the solution was subjected to hydrogenation for 2 hours at room temperature in the presence of 0.6 g of 10% palladium-carbon.
  • the hydrogenation mixture was filtered over "Celite” (Trade Mark) filter aid, and the filtrate was extracted with 80 ml of ether.
  • the aqueous layer was concentrated under reduced pressure and the concentrate was subjected to chromatography through a 160 ml column of "Dowex 50W" (Trade Mark) cation exchange resin (Na + type), giving 68 mg of the title product from the fraction eluted with water.
  • Example 1(3) The procedure of Example 1(3) was repeated, except that 100 mg of p-nitrobenzyl (1R,5R,6S)-6-[(1R)-1-hydroxyethyl]-1-methyl-2-oxo-1-carbapenam-3-carboxylate and 90 mg of 2-(4-methyl-3-oxopiperazin-1-yl)-2-iminoethylmercaptan hydrochloride were used. After hydrogenation and filtration over "Celite" (Trade Mark) filter aid, the filtrate was extracted twice with 20 ml portions of diethyl ether.
  • Celite Trade Mark
  • aqueous phase was concentrated by evaporation under reduced pressure, and the residue was purified by chromatography through a Lobar column (Merck “LiChloprep RP-8", size B, two columns), eluted with 2% aqueous methanol, to give 10 mg of the title compound.
  • aqueous phase was concentrated by evaporation under reduced pressure and the residue was purified through a Lobar column (Merck “LiChloprep RP-8", size B, two columns), eluted with 5% aqueous methanol, to give the title compound having the same properties as those of the product obtained in Example 13.
  • the solvent was removed, the residue was dissolved in 920 ml of ethanol, 13.1 g of potassium fluoride were added to the solution, and the mixture was stirred at room temperature for 1.5 hours.
  • the reaction mixture was concentrated, and the concentrate was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution.
  • the solvent was removed and the concentrate was chromatographed through a column packed with 1.3 kg of silica gel.
  • This oil was dissolved in 100 ml of toluene and the solution mixed with 2.6 ml of triethyl phosphite. The mixture was heated at 140° C. for about 12 hours under a nitrogen atmosphere. The solvent and excess of triethyl phosphite were distilled off from the reaction mixture, and the product was recovered and purified by chromatography through two Lobar columns (Merck “LiChroprep Si60", Size B).
  • reaction mixture was then diluted with ethyl acetate and washed successively with saturated aqueous sodium chloride solution, 5% aqueous sodium bicarbonate solution, and again saturated aqueous sodium chloride solution.
  • the solvent was distilled off, and the resulting residue was chromatographed on a column of silica gel using a 3/1 mixture of benzene/ethyl acetate as eluent, giving 57 mg of the title compound as pale yellow crystals.
  • reaction mixture was chromatographed on a column of silica gel, and a fraction eluted with a 4/1 mixture of cyclohexane/ethyl acetate was worked up to give 0.914 g of (3S,4S)-3-[(1R)-1-trimethylsilyloxyethyl]-4-[(1RS)-1-(phenylthiocarbonyl)ethyl]-2-azetidinone as an oil.
  • This oil was dissolved in 100 ml of toluene and the solution mixed with 2.6 ml of triethyl phosphite. The resulting mixture was heated at 140° C. for about 12 hours under a nitrogen atmosphere. The solvent and excess triethyl phosphite were distilled off under reduced pressure. The residue was dissolved in 14 ml of a 4/1 mixture of tetrahydrofuran and water, mixed with 70 mg of pyridinium p-toluenesulfonate, and allowed to stand for one hour at room temperature. A saturated aqueous solution of sodium chloride was added, and the mixture was extracted with ethyl acetate.
  • the mixture was stirred at the same temperature for a further 5 minutes, and the stirring was then continued while allowing its temperature to rise to ambient.
  • the reaction mixture was mixed with 100 ml of water and extracted with methylene chloride.
  • the organic extract was washed with saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate.
  • the solvent was distilled off and the residue was chromatographed on a silica gel column, eluted with a 2/1 mixture of benzene and ethyl acetate, giving 3.61 g of 1-(t-butoxycarbonyl)-3-pyrrolidone as an oil.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
US06/856,696 1985-04-27 1986-04-25 Carbapenem derivatives Expired - Fee Related US4771046A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP60-91988 1985-04-27
JP9198885 1985-04-27

Publications (1)

Publication Number Publication Date
US4771046A true US4771046A (en) 1988-09-13

Family

ID=14041841

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/856,696 Expired - Fee Related US4771046A (en) 1985-04-27 1986-04-25 Carbapenem derivatives

Country Status (17)

Country Link
US (1) US4771046A (da)
EP (1) EP0202048B1 (da)
JP (1) JPH0710868B2 (da)
KR (1) KR920010076B1 (da)
AT (1) ATE69053T1 (da)
AU (1) AU583113B2 (da)
CA (1) CA1305709C (da)
DE (1) DE3682225D1 (da)
DK (1) DK189686A (da)
ES (1) ES8800952A1 (da)
FI (1) FI81577C (da)
HU (1) HU194882B (da)
IE (1) IE58892B1 (da)
NO (1) NO163452C (da)
NZ (1) NZ215957A (da)
PH (1) PH22555A (da)
ZA (1) ZA863109B (da)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310735A (en) * 1990-02-23 1994-05-10 Sankyo Company, Limited Carbapenem derivatives having antibiotic activity, their preparation and their use
US5712267A (en) * 1991-06-04 1998-01-27 Sankyo Company,. Limited Carbapenem derivatives, their preparation and their use as antibiotics
US5932048A (en) * 1995-04-06 1999-08-03 Komatsu Electronic Metals Co., Ltd. Method of fabricating direct-bonded semiconductor wafers
US20070234661A1 (en) * 2005-01-28 2007-10-11 Ed Vaes Multi piece curved moldings

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0759581B2 (ja) * 1986-09-05 1995-06-28 日本レダリ−株式会社 （１ｒ）−１−メチルカルバペネム−３−カルボン酸誘導体
JPS6425780A (en) * 1987-04-28 1989-01-27 Sankyo Co 1-methylcarbapenem derivative
CN1046729C (zh) 1994-09-16 1999-11-24 万有制药株式会社 新的碳代青霉烯衍生物
CA2199855A1 (en) * 1994-09-16 1996-03-21 Ryosuke Ushijima Novel carbapenem derivative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071908A1 (en) * 1981-08-03 1983-02-16 Merck & Co. Inc. 1-, and 1,1-disubstituted-6-substituted-2-carbamimidoyl-1-carbadethiapen-2-em-3-carboxylic acids, a process for preparing and an antibiotic composition containing the same
US4477662A (en) * 1981-02-04 1984-10-16 Beecham Group P.L.C. 2-Substituted thio carbapenem derivatives
JPS60178888A (ja) * 1984-02-22 1985-09-12 Sankyo Co Ltd ペネムまたはカルバペネム誘導体およびその製法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK165280A (da) * 1979-04-19 1980-10-20 Merck & Co Inc Fremgangsmaade til fremstilling af 2- og 6-substituerede 1-carbadethiapen-2-em-3-carboxylsyrer og mellemprodukter til brug ved udoevelse af fremgangsmaaden
PT73791B (en) * 1980-10-17 1983-10-14 Merck & Co Inc Process for preparing 2-carbamimidoyl-6-substituted-1- -carbadethiapen-2-em-3-carboxylic acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477662A (en) * 1981-02-04 1984-10-16 Beecham Group P.L.C. 2-Substituted thio carbapenem derivatives
EP0071908A1 (en) * 1981-08-03 1983-02-16 Merck & Co. Inc. 1-, and 1,1-disubstituted-6-substituted-2-carbamimidoyl-1-carbadethiapen-2-em-3-carboxylic acids, a process for preparing and an antibiotic composition containing the same
JPS60178888A (ja) * 1984-02-22 1985-09-12 Sankyo Co Ltd ペネムまたはカルバペネム誘導体およびその製法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310735A (en) * 1990-02-23 1994-05-10 Sankyo Company, Limited Carbapenem derivatives having antibiotic activity, their preparation and their use
US5420119A (en) * 1990-02-23 1995-05-30 Sankyo Company, Limited Carbapenem derivatives having antibiotic activity, their preparation and their use
US5712267A (en) * 1991-06-04 1998-01-27 Sankyo Company,. Limited Carbapenem derivatives, their preparation and their use as antibiotics
US5866564A (en) * 1991-06-04 1999-02-02 Sankyo Company, Limited Carbapenem derivatives, their preparation and their use as antibiotics
US5932048A (en) * 1995-04-06 1999-08-03 Komatsu Electronic Metals Co., Ltd. Method of fabricating direct-bonded semiconductor wafers
US20070234661A1 (en) * 2005-01-28 2007-10-11 Ed Vaes Multi piece curved moldings

Also Published As

Publication number Publication date
IE58892B1 (en) 1993-12-01
FI861763A0 (fi) 1986-04-25
ES554474A0 (es) 1987-12-01
NO163452B (no) 1990-02-19
FI81577B (fi) 1990-07-31
DK189686D0 (da) 1986-04-24
EP0202048A1 (en) 1986-11-20
JPH0710868B2 (ja) 1995-02-08
KR860008178A (ko) 1986-11-12
AU5671086A (en) 1986-10-30
NZ215957A (en) 1988-04-29
ES8800952A1 (es) 1987-12-01
HUT40661A (en) 1987-01-28
DE3682225D1 (de) 1991-12-05
AU583113B2 (en) 1989-04-20
EP0202048B1 (en) 1991-10-30
NO861630L (no) 1986-10-28
JPS6230781A (ja) 1987-02-09
ATE69053T1 (de) 1991-11-15
DK189686A (da) 1986-10-28
PH22555A (en) 1988-10-17
HU194882B (en) 1988-03-28
IE861106L (en) 1986-10-27
NO163452C (no) 1990-05-30
CA1305709C (en) 1992-07-28
FI861763A7 (fi) 1986-10-28
ZA863109B (en) 1986-12-30
KR920010076B1 (ko) 1992-11-13
FI81577C (fi) 1990-11-12

Similar Documents

Publication Publication Date Title
EP0165384B1 (en) Carbapenem derivatives, their preparation and compositions containing them
EP0160391B1 (en) Carbapenem derivatives and compositions containing them
EP0337637A1 (en) 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics
AU711135B2 (en) 1-methylcarbapenem derivatives
US4771046A (en) Carbapenem derivatives
US4740507A (en) Carbapenem compounds and use
HU218676B (hu) Antimikrobiális karbapenemszármazékok, ilyen vegyületeket tartalmazó gyógyászati készítmények és eljárás ezek előállítására
EP0449191B1 (en) 2-(Substituted pyrrolidinylthio)carbapenem derivatives
RU2162088C2 (ru) 1-метилкарбапенем или его фармакологически приемлемые соли, композиция, способ предупреждения или лечения бактериальных инфекций
US4613595A (en) Penem derivatives, and composition containing them
EP1340756B1 (en) Novel beta-lactam compounds and process for producing the same
AU651505B2 (en) Aminoalkylpyrrolidinylthiocarbapenem derivatives
EP0017970A1 (en) Novel beta-lactam derivatives and process for production thereof
US5373002A (en) 2-(substituted pyrrolidinylthio) carbapenem derivatives
HK1122800A (en) Novel beta-lactam compounds and process for producing the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANKYO COMPANY, LIMITED, 1-6, 3-CHOME, NIHONBASHI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KAWAMOTO, ISAO;ENDO, ROKURO;IWATA, MASAYUKI;REEL/FRAME:004547/0929

Effective date: 19860423

Owner name: SANKYO COMPANY, LIMITED, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAWAMOTO, ISAO;ENDO, ROKURO;IWATA, MASAYUKI;REEL/FRAME:004547/0929

Effective date: 19860423

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19960918

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362